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Abstract: Glycated albumin (GA) exhibits atherogenic effects and
increased serum GA levels are associated with the development of
cardiovascular complications in diabetic patients. GA production also
increases with aging, oxidative stress, and renal dysfunction. We
performed this study to further ascertain the association between GA
and arterial stiffness in nondiabetic chronic kidney disease (CKD)
patients.
We enrolled 129 nondiabetic CKD patients. Arterial stiffness was
measured by brachial-ankle pulse wave velocity (baPWV) using a
volume plethysmographic instrument along with simultaneous
measurements of GA. Insulin resistance was determined with the
homeostatic model assessment. The estimated glomerular filtration
rate was calculated using serum creatinine and cystatin C according to
the CKD-EPI Creatinine-Cystatin C equation adjusted for age, sex, and
race (eGFRcr-cys).
Nondiabetic CKD patients with arterial stiffness (baPWV
1400 cm/s) showed higher GA levels than those without arterial
stiffness (14.2 [8.7–20.2]% vs 13.0 [8.8–18.9]%, P¼ 0.004). In the
subgroup analysis, the patients who had both a higher GA level and a
lower eGFRcr-cys, showed the highest baPWV compared with
patients with a higher GA or a lower GFR alone.
By Spearman’s correlation analysis, GA correlated significantly
with baPWV (r¼þ0.291, P¼ 0.001) and fasting serum glucose level
(r¼þ0.191, P¼ 0.030), whereas The homeostatic model assessment
of insulin resistance did not show any significant correlation with
baPWV. Systolic blood pressure (r¼þ0.401 P< 0.001), age
(r¼þ0.574, P< 0.001), high-density lipoprotein (HDL)-cholesterol
level (r¼0.317, P< 0.001), and eGFRcr-cys (r¼0.285,
P¼ 0.002) had a significant correlation with baPWV. According to
multivariable logistic regression analysis, higher GA and systolic
blood pressure were the independent risk factors affecting arterialMD, Gi Young Yun Choi, MD,
PhD, and Hyeong Cheon Park, MD, PhD
(Medicine 95(16):e3362)
Abbreviations: ACEi = angiotensin-converting enzyme inhibitors,
AGEs = advanced glycation end products, ARB = angiotensin II-
receptor blockers, AUC = area under the ROC curve, baPWV =
brachial-ankle pulse wave velocity, BMI = body mass index, CCB
= calcium channel blockers, CKD = chronic kidney disease, CVD =
Cardiovascular disease, eGFRcr-cys = estimated glomerular
filtration rate calculated using serum creatinine and cystatin C
according to the CKD-EPI Creatinine-Cystatin C equation, GA =
Glycated albumin, HbA1C = glycated hemoglobin, HOMA-IR =
The homeostatic model assessment of insulin resistance, NF-kB =
nuclear factor–kappa B, ROC = receiver-operating characteristic,
UPCR = urine protein-creatinine ratio.
INTRODUCTION
C ardiovascular disease (CVD) is a major cause of death inchronic kidney disease (CKD) patients.1,2 The Second
National Health and Nutrition Examination Survey showed that
even a mild-to-moderate renal insufficiency was independently
associated with subsequent death from CVD.3,4 However, this
higher cardiovascular morbidity and mortality observed in CKD
patients cannot be fully explained by traditional risk factors
alone. Inflammation, malnutrition, endothelial dysfunction, and
albuminuria are frequently observed in CKD patients and they
have been reported as nontraditional risk factors contributing to
increased cardiovascular mortality rate.5
Increased arterial stiffness plays an important role in the
causation of CVD in CKD patients and is regarded as a
nontraditional risk factor for CVD in CKD patients. Moreover,
several studies have suggested that arterial stiffness itself may
also contribute to the progression of CKD.6–8 Arterial stiffness
in CKD patients is of multifactorial etiologies including old age,
vascular calcification, hypertension, inflammation, uremic tox-
ins, and the renin-angiotensin-aldosterone system.9 Recent
studies have identified accumulation of advanced glycation
end products (AGEs) as a novel contributor to arterial stiffen-
ing. AGE formation is markedly enhanced in diabetics because
of sustained hyperglycemia. In uremia, however, the presence
of carbonyl stress contributes to AGE modification of proteins,
and plasma AGE levels rise dramatically, independent of
hyperglycemia. Therefore, AGE concentrations in excess of
normal aging or diabetes are frequently found in uremic plasma,
irrespective of the presence of diabetes. The accumulation of
AGEs or binding of AGEs to receptors in the vessel wall is
associated with the cross-linking of collagen and induction of
cell signaling, which result in oxidative stress, increased expres-
sion of cytokines and adhesion molecules, and activation ofB (NF-kB). The augmentation of these
he increased arterial stiffness observed in
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Glycated albumin (GA), a precursor for generation of
AGEs, is the major form of circulating Amadori-type glycated
proteins. It has been reported to be a better glycemic indicator
than glycated hemoglobin (HbA1C) in hemodialysis patients
with diabetes. In addition to its role as a sensitive marker of
glycemic status, there is growing evidence that GA is associated
with increased oxidative stress and endothelial injury resulting
in diabetic vasculopathy.14 Increased GA concentrations are
associated with accelerated atherosclerosis as well as presence
and severity of coronary artery disease in type 2 diabetic
patients.14–17 Furthermore, GA demonstrated significant
positive correlation with arterial stiffness measured by bra-
chial-ankle pulse wave velocity (baPWV) values in diabetic
hemodialysis patients.18 These studies support the role of GA in
predicting diabetic vascular complications.
In nondiabetic participants with mild-to-advanced CKD,
GA levels were shown to have a significant negative correlation
with glomerular filtration rate (GFR) and were independent of
HbA1C, hematocrit, systolic blood pressure, body mass index
(BMI), and the amount of proteinuria.19 Few clinical studies
have examined the role of GA in predicting nondiabetic vas-
cular complications. Therefore, we aimed to investigate
whether elevated GA levels are associated with increased
arterial stiffness in nondiabetic CKD patients.
METHODS
Participants
One hundred twenty-nine nondiabetic CKD patients were
enrolled during their routine clinical visits between March 2012
and October 2013. All patients were diagnosed with CKD
according to the National Kidney Foundation K/DOQI Guide-
lines based on an estimated GFR (eGFR) of <60mL/min/
1.73m2 with or without the presence of kidney damage. Kidney
damage for >3 months was defined as structural or functional
abnormalities of the kidney with or without decreased GFR,
manifested by either pathologic abnormalities or markers of
kidney damage including abnormalities in the composition of
the blood or urine or on imaging tests.20 The eGFR was
calculated by serum creatinine and cystatin C using the
CKD-EPI creatinine-cystatin C equation adjusted for age,
sex, and race.21 A medical history and a physical examination
were performed to gather additional information, including sex,
underlying disease that may have caused CKD, comorbidity
including cardiovascular disease and cerebrovascular disease,
use of antihypertensive agents (such as calcium channel block-
ers, angiotensin-receptor antagonists, or angiotensin-converting
enzyme inhibitors), statin use, blood pressure, and BMI (kg/m2).
The laboratory findings measured on the day of baPWVassess-
ment such as hemoglobin, fasting serum glucose, insulin,
albumin, total cholesterol, triglycerides, high-density lipopro-
tein (HDL)-cholesterol, low-density lipoprotein (LDL)-choles-
terol, serum creatinine, blood urea nitrogen, cystatin C, urine
protein-creatinine ratio (UPCR), and GA were included in this
study. Serum GA levels were determined using an enzymatic
method (Hitachi 7600 P module auto-analyzer, Hitachi Instru-
ments Service, Tokyo, Japan). The coefficient of variation for
GA was 2.49% at 0.6 g/dL and 1.81% at 1.5 g/dL. Insulin
resistance was calculated by the homeostatic model assessment
of insulin resistance (HOMA-IR) index (plasma glucose
[mmol] [plasma insulin level/22.5]).22,23
Choi et alThis study was approved by the Institutional Review Board
(3–2014–0234) of Gangnam Severance Hospital, Yonsei Uni-
versity College of Medicine, Seoul, Korea.
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Arterial stiffness was assessed by baPWV, as previously
reported.24 Patients had abstained from caffeine and any other
medications, including antihypertensive agents, for at least
12 hours before the baPWV assessment. The baPWV measure-
ments were obtained at the bedside of each participant using a
volume plethysmographic instrument (VP 1000, OMRON
Healthcare, Kyoto, Japan). Assessments of both baPWV values
were performed after at least 5 minutes of rest in the supine
position in an air-conditioned room (248C 268C). For our
analysis, the mean baPWV was used. The validity, reliability,
and reproducibility of this instrument were assessed in a
previous study.24 The participants with baPWV value of
1400 cm/s were defined as ‘‘Stiffness’’ group, whereas those
with baPWV <1400 cm/s were grouped as ‘‘non-stiffness’’
group, as previously reported.25
Statistical Analysis
Statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS1) version 20.0 (SPSS
Inc, Chicago, IL). All continuous variables are described as the
median (interquartile range) based on results fromKolmogorov-
Smirnov tests, which identified data that were not normally
distributed. Categorical data are expressed as the number with
percentages. Statistical comparisons between groups were per-
formed using Mann-Whitney U tests or x2 tests, both nonpara-
metric statistical methods. Spearman correlation coefficient was
used for comparisons between pairs of variables. The predictive
values of HOMA-IR, fasting glucose, and GA for increased
baPWV were calculated by constructing receiver-operating
characteristic (ROC) curves, and comparison of the ROC curves
was performed using the Delongmethod. The value of the cutoff
point for GA for predicting arterial stiffness was calculated
using the Youden method.26
Multivariable logistic regression analyses were used to
estimate multiple correlations between arterial stiffness and
clinical and laboratory risk factors. A P value of <0.05 was
considered to be statistically significant. P values were
calculated after (Holm)-Bonferroni correction for multiple
testing.
RESULTS
Characteristics of Participants
The baseline characteristics of participants are shown in
Table 1. In all 129 nondiabetic CKD patients (62 men and 67
women) with a median age of 58 (29–82) years were included
in this study. The causes of CKD were 60 cases of hypertension
(45.7%), 33 cases of glomerulonephritis (25.6%; IgA nephro-
pathy: 23, minimal change disease: 3, ANCA-associated glo-
merulonephritis: 3, membranous nephropathy: 1, focal
segmental glomerulosclerosis: 2, post-streptococcal glomeru-
lonephritis: 1), 7 cases of other conditions such as polycystic
kidney disease (5.4%), and 29 cases with an unknown etiology
(22.5%). One hundred eleven patients had taken anti-hyperten-
sive medications such as calcium channel blockers (CCB),
angiotensin II-receptor blockers (ARB) or angiotensin-convert-
ing enzyme inhibitors (ACEi) or some combination of these
medications. Eighty-three patients had been prescribed statins.
The median level of eGFRcr-cys was 54mL/min/1.73m2 and
Medicine  Volume 95, Number 16, April 2016the median GA levels were 13.6%. The median baPWV was
1456.5 cm/s. Patient characteristics for males and females are
included in sTable 1, http://links.lww.com/MD/A893.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Characteristics of the Whole Study Participants
Non-diabetic CKD patients (%)
Age, y 58 (29–82)
Sex (male:female) 62: 67
Cause of CKD
Hypertensive nephrosclerosis 60 (45.7%)
Glomerulonephritis 33 (25.6%)
Others 7 (5.4%)
Unknown 29 (22.5%)
Cardiovascular disease 18 (14.0%)
Cerebrovascular disease 12 (9.3%)
ACEi or ARB use 101 (78.3%)
CCB use 35 (27.1%)
Statin use 83 (64.3%)
BMI, kg/m2 23.8 (15.9–33.9)
Systolic blood pressure, mmHg 127 (92–187)
Diastolic blood pressure, mmHg 80 (56–121)
Total cholesterol, mg/dL 166 (116–279)
Triglyceride, mg/dL 112.5 (41.0–441.0)
HDL-cholesterol, mg/dL 44 (27–110)
LDL-cholesterol, mg/dL 96 (48–217)
Albumin, g/dL 4.4 (3.0–5.0)
eGFRcr-cys, mL/min1.73m2 54 (7–127)
UPCR, mg/g 185.8 (3.7–6920.0)
Fasting glucose, mg/dL 95 (67–142)
Fasting insulin, mIU/mL 7.9 (2.1–29.6)
HOMA-IR 1.9 (0.5–7.7)
GA, % 13.6 (8.7–20.2)
baPWV, cm/s 1456.5 (1085.5–2956.0)
Data are expressed as number (%) or median (interquartile range).
ACEi¼ angiotensin-converting enzyme inhibitors, ARB¼ angiotensin
II-receptor blockers, baPWV¼ brachial-ankle pulse wave velocity,
BMI¼ body mass index, CCB¼ calcium channel blockers, eGFRcr-
cys¼ estimated GFR measured by serum creatinine and cystatin C,
Medicine  Volume 95, Number 16, April 2016Table 2 shows the clinical characteristics and biochemical
findings of the patients who were classified by arterial stiff-
ness. Seventy-five patients (58.1%) reported increased arterial
stiffness (baPWV 400 cm/s, ‘‘stiffness group’’). Age, the
number of patients with CVD systolic blood pressure, and
baPWV were significantly higher, whereas HDL-cholesterol
and eGFRcr-cys were lower in the ‘‘stiffness’’ group than in
the ‘‘non-stiffness’’ group. The ‘‘stiffness’’ group showed
higher GA levels than the ‘‘non-stiffness’’ group (14.2
[8.7–20.2]% vs 13.0 [8.8–18.9]%, P¼ 0.004, Table 2). How-
ever, other glycemic indices, including fasting glucose, insulin,
and HOMA-IR did not reveal any significant differences
between the 2 groups (Table 2).
We also constructed receiver-operating characteristics
(ROC) curves to predict arterial stiffness based on GA levels
or other glycemic indices. The area under the ROC curve (AUC)
of GA levels for arterial stiffness was significantly larger than
that of HOMA-IR or fasting glucose levels (AUC of GA
levels¼ 0.677; 95% CI, 0.581–0.773 vs AUC of HOMA-
IR¼ 0.541; 95% CI, 0.439–0.644, AUC of fasting glucose
GA¼Glycated albumin, HOMA-IR¼The homeostatic model assess-
ment of insulin resistance, UPCR¼ urine protein-creatinine ratio.levels¼ 0.551; 95% CI, 0.446–0.656) (Figure 1A). According
to the Youden method, the value of the cutoff point for GA was
13.6% for predicting arterial stiffness in all participants
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.(sensitivity [95% CI]: 64 [52.1–74.8]; specificity [95% CI]:
75.9 [62.4–86.5]; PPV [95% CI]: 76.2 [65.7–86.7]; NPV [95%
CI]: 59.1 [47.3–71.0]).
Subgroup Analyses According to GA and Renal
Function
We classified all participants according to their GA levels.
Table 3 shows the characteristics and biochemical findings of
the participants who were grouped by their GA levels. Sixty-
four patients (49.6%) had higher GA levels than the cutoff point
of GA (13.6%). Age was significantly higher and eGFRcr-cys
were lower in the ‘‘Higher GA’’ group than in the ‘‘Lower GA’’
group. The ‘‘Higher GA’’ group showed significant arterial
stiffness compared with that of the ‘‘Lower GA’’ (baPWV
1534.8 [1096.0–2956.0] vs 1360.5 [1085.5–2219.5] cm/s,
P< 0.001) (Table 3).
Next, 52 patients (40.3%) were classified in the ‘‘Lower
GFR group’’ (eGFRcr-cys less than 60mL/min/1.73m2),
whereas 77 patients (59.7%) were classified in the ‘‘Higher
GFR group’’ (eGFRcr-cys greater than 60mL/min/1.73m2). In
the ‘‘Lower GFR’’ group, UPCR and GA levels were higher,
and eGFRcr-cys values were lower than those in the ‘‘Higher
GFR’’ group (Table 3). Similar to the patients with higher GA
levels, the ‘‘Lower GFR’’ group also revealed a significantly
higher baPWV than the ‘‘Higher GFR’’ group (baPWV 1522.5
[1092.5–2956.0] vs 1385.8 [1085.5–2134.0] cm/s, P¼ 0.011)
(Table 3).
To investigate the compound effects of renal function and
higher GA levels of patients on arterial stiffness, the patients
were classified into 4 groups (Group I: participants with a GA
>13.6% and eGFRcr-cys <60mL/min/1.73m2; Group II:
participants having a GA >13.6% and eGFRcr-cys 60mL/
min/1.73m2; Group III: participants with a GA 13.6% and
eGFRcr-cys <60mL/min/1.73m2; Group IV: participants hav-
ing a GA 13.6% and eGFRcr-cys 60mL/min/1.73m2). As a
result, the patients who had higher GA levels with a lower eGFR
(Group I) showed the highest baPWV among the 4 subgroups
(Group I: 1573.5 [1206.0–2956.0] cm/s; Group II: 1408.8
[1096.0–2034.0] cm/s; Group III: 1364.3 [1092.5–2219.5]
cm/s; Group IV: 1360.0 [1085.5–2134.0] cm/s, P< 0.001).
However, no significant differences were found between the
group with a lower GA and a higher GFR and the group with a
higher GA alone or the group that only had lower eGFR
(P¼ 0.838) (Figure 1B).
Association of baPWV with Glycemic Indices and
Cardiovascular Risk Factors
Figure 2 shows the Spearman analysis coefficients
between baPWV and the variables for glycemic indices and
cardiovascular risk in the enrolled participants. In all partici-
pants, baPWV correlated significantly with GA (r¼þ0.291,
P¼ 0.001) and fasting glucose level (r¼þ0.191, P¼ 0.030),
whereas HOMA-IR did not show any significant correlation
with baPWV (Figure 2A, B, and C). Systolic blood pressure
(r¼þ0.401 P< 0.001) and age (r¼þ0.574, P< 0.001) were
significantly associated with baPWV (Figure 2D, E). HDL-
cholesterol level (r¼0.317, P< 0.001) and eGFRcr-cys
(r¼0.285, P¼ 0.002) showed a significant negative corre-
lation with baPWV (Figure 2F, G).
For multivariable logistic regression analysis, higher GA,
Glycated Albumin in Non-Diabetic Chronic Kidney Diseaselower eGFRcr-cys, fasting glucose, and other conventional risk
factors, including age group with cardiovascular risk (male>45
years, female>55 years), male sex, systolic blood pressure, and
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TABLE 2. Participant Characteristics Classified by Arterial Stiffness
Non-stiffness Group (n¼ 54) Stiffness Group (n¼ 75) P
Age, y 50.5 (29–67) 63.0 (33–82) <0.001
Sex, male (%) 42.6% 53.3% 0.855
Hypertension, yes (%) 85.2% 86.7% 2.409
Cardiovascular disease, yes (%) 5.7% 20.0% 0.018
Cerebrovascular disease, yes (%) 5.6% 12.0% 1.071
ACEi or ARB use, yes (%) 81.5% 76.0% 1.563
CCB use, yes (%) 18.5% 33.3% 0.219
Statin use, yes (%) 59.3% 68.0% 1.005
BMI, kg/m2 22.3 (16.9–33.9) 23.9 (15.9–32.0) 0.127
Systolic blood pressure, mmHg 121 (92–155) 129 (103–187) 0.013
Diastolic blood pressure, mmHg 78 (56–121) 81 (56–106) 0.483
Total cholesterol, mg/dL 169 (124–236) 162 (116–279) 0.440
Triglyceride, mg/dL 107.5 (47–333) 114 (41–441) 1.033
HDL-cholesterol, mg/dL 49.5 (28–110) 42 (27–89) 0.045
LDL-cholesterol, mg/dL 97 (58–165) 95 (48–217) 0.627
Albumin, g/dL 4.4 (3.6–5.0) 4.4 (3.0–4.9) 1.349
eGFRcr-cys, mL/min/1.73m2 65 (7–127) 47.5 ((7–108) 0.025
UPCR, mg/g 184.7 (13.4–4112.6) 197.8 (3.7–6920.0) 1.668
Fasting glucose, mg/dL 93 (67–126) 97 (74–142) 0.581
Fasting insulin, mIU/mL 7.5 (2.4–20.8) 8.3 (2.1–29.6) 1.365
HOMA-IR 1.8 (0.5–5.5) 1.9 (0.5–7.7) 1.306
GA, % 13.0 (8.8–18.9) 14.2 (8.7–20.2) 0.004
baPWV, cm/s 1314.0 (1085.5–1719.5) 1615.0 (1396.5–2956.0) <0.001
Data are expressed as number (%) or median (interquartile range). Means were tested by unpaired t test and Mann-Whitney test. P values<0.05 are
significant compare with the non-stiffness group.
ACEi¼ angiotensin-converting enzyme inhibitors, ARB¼ angiotensin II-receptor blockers, baPWV¼ brachial-ankle pulse wave velocity,
BMI¼ body mass index, CCB¼ calcium channel blockers, eGFRcr-cys¼ estimated GFR measured by serum creatinine and cystatin C, GA¼
insu
Choi et al Medicine  Volume 95, Number 16, April 2016serum HDL-cholesterol, were entered as the independent
variables affecting arterial stiffness. Higher GA (OR 2.883,
Glycated albumin, HOMA-IR¼The homeostatic model assessment ofP¼ 0.015) and systolic blood pressure (OR 1.034, P¼ 0.015)
were significant independent factors affecting arterial stiffness
(Table 4).
FIGURE 1. Receiver-operating characteristic (ROC) curve and Brach
glycemic indices predicting arterial stiffness (A). Brachial–ankle pulse w
and lower glomerular filtration rate (GFR); Group II: higher GA and high
higher GFR (B).
4 | www.md-journal.comDISCUSSION
CKD patients face exceptionally increased CVDmorbidity
lin resistance, UPCR¼ urine protein-creatinine ratio.and mortality that is characterized by arteriosclerosis and
increased arterial stiffness.8 This increased arterial stiffness
in CKD patients cannot be fully explained by conventional
ial–ankle pulse wave velocity in subgroups. ROC curve of each
ave velocity in subgroups. Group I: higher glycated albumin (GA)
er GFR; Group III: lower GA and lower GFR; Group IV: lower GA and
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
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FIGURE 2. Correlation between brachial–ankle pulse wave velocity and glycated albumin (A), fasting glucose (B), HOMA-IR (C), systolic
blood pressure (D), age (E), HDL-cholesterol (F), eGFRcr-cys (G) in the entire subjects. baPWV; brachial–ankle pulse wave velocity, HOMA-
h-
ocit
HO
Choi et al Medicine  Volume 95, Number 16, April 2016risk factors alone. Nontraditional risk factors, such as inflam-
mation, endothelial dysfunction, and bone mineral derange-
ments, have been implicated in the development of arterial
stiffness in CKD.27 Furthermore, recent efforts have focused on
identifying additional factors that may account for the link
between CKD and arterial stiffness.
The present study demonstrated that GA was an indepen-
dent risk factor for increased arterial stiffness in nondiabetic
CKD patients and those with an increased GA and impaired
renal function had higher arterial stiffness than those who only
demonstrated increased GA or impaired renal function alone.
The formation of AGEs is an important pathway in the
development of arterial stiffness in diabetic patients. Recent
experimental studies have proposed that GA may also play a
role in the mechanism of increased arterial stiffness in diabetes.
In vitro experiments have demonstrated that GA promotes
IR; The homeostaticmodel assessment of insulin resistance, HDL: hig
creatinine and cystatin C. baPWV¼brachial-ankle pulse wave vel
serum creatinine and cystatin C, HDL¼high-density lipoprotein,inflammation via NF-kB activation in endothelial cells and
stimulates vascular smooth muscle cell proliferation.14,28,29
Moreover, increased GA has been found to upregulate NADPH
TABLE 4. Logistic Regression Analysis for the Determinants of Ar
b Coefficient
Higher GA group (>13.6%) 0.196
Lower eGFRcr-cys group (<60mL/min/1.73m2) 0.492
Fasting glucose 0.010
Age group (male >45, female >55 y) 0.817
Male sex 0.033
Systolic blood pressure, mmHg 0.033
HDL-cholesterol 0.025
CI¼ confidence interval, eGFRcr-cys¼ estimated GFRmeasured by serum
b¼ standard error of b coefficient.
6 | www.md-journal.comoxidase and induce sustained reactive oxygen species pro-
duction in human endothelial cells.30 Diabetic db/db mice
treated with anti-GA antibodies normalized plasma levels of
fibronectin, a marker of endothelial damage, despite persistent
hyperglycemia.31 A recent cross-sectional study demonstrated
that GA was associated with carotid intima-media thickness
(IMT) in patients with type 2 diabetes mellitus without any
coronary heart disease and peripheral artery disease.32 More-
over, a retrospective longitudinal study has shown that the
serum level of GA predicted progression of carotid IMT in
patients with type 2 diabetes mellitus after adjustment of
common atherogenic risk factors such as age, sex, and LDL-
cholesterol.15 Taken together, GA could be considered to be an
atherogenic protein in the development of diabetic atheroscle-
rosis.15,32 Although there is no direct histologic evidence
demonstrating GA involvement in arterial stiffness, the above
density lipoprotein, eGFRcr-cys; estimated GFRmeasured by serum
y, eGFRcr-cys¼ estimated glomerular filtration rate measured by
MA-IR¼homeostatic model assessment of insulin resistance.findings suggest that increased GA causally contributes to
diabetic vasculopathy. The present study identified a relation-
ship between GA and PWV independent of fasting glucose and
terial Stiffness
SE b OR 95% CI for OR P
0.102 2.883 1.227–6.772 0.015
0.426 1.389 0.585–3.295 0.456
0.018 1.009 0.974–1.045 0.612
0.460 2.183 0.880–5.415 0.092
0.433 0.972 0.414–2.281 0.949
0.014 1.034 1.007–1.063 0.015
0.017 0.972 0.939–1.005 0.094
creatinine and cystatin C, GA¼ glycated albumin, OR¼ odds ratio, SE
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
insulin resistance in non-diabetic CKD patients. These results
suggest that GA could be a biomarker of arterial stiffness
beyond glucose metabolism in nondiabetic CKD patients.
Ma et al implied that the impact of GA to eGFR could be
masked because the glycemic status strongly affects the GA
concentration in diabetic patients. They demonstrated that GA
concentrations were significantly correlated with GFR only in
nodiabetic CKD patients even after adjusting for proteinuria,
hematocrit, HbA1C, systolic blood pressure, BMI, and total
cholesterol in multivariate analysis.15,20 Our results showed that
participants with higher GA levels had significantly lower
eGFRcr-cys and also demonstrated the significant negative
association between eGFRcr-cys and GA levels in nondiabetic
CKD patients (data not shown). However, we did not find any
significant association between eGFRcr-cys and baPWV after
adjusting GA levels, age, sex, and HDL-cholesterol levels. GA
might be considered as a powerful risk factor affecting on
arterial stiffness in non-diabetic CKD patients regardless of
renal function in the present study.
GA was also reported to stimulate TGF-b and increase
oxidative stress, which could induce vasculopathy in exper-
imental models.29 Therefore, the accumulation of GA as a result
of impaired renal clearance was assumed to play an important
role in the progression of vasculopathy in CKD patients via the
promotion of oxidative stress, production of inflammatory
cytokines, and endothelial damage.14
On the contrary, several recent studies have reported that
the association of arterial stiffness with different stages of CKD
or GFR was unsubstantiated. Although the univariate analysis
showed a significant association of arterial stiffness and GFR,
traditional risk factors for CVD might be more important
determinants of arterial stiffness than GFR in multivariate
analysis.25,36,37 In stage 3 CKD patients, eGFR was not an
independent determinant, but traditional risk factors including
age, mean arterial pressure, and diabetes were the strongest
independent determinants of a higher PWV.33 Sengstock et al
reported a significant relationship between GFR and PWV, but
only 2% of the variation in PWV could be explained by GFR in
multivariate analysis when conventional determinants of arter-
ial stiffness, including age, systolic blood pressure, diabetes,
and obesity, were analyzed as covariates.34–36 These results
suggested that previous reports regarding the relationship of
renal insufficiency and arterial stiffness might be attributable to
common underlying CVD risk factors in CKD patients. The
present study also demonstrated that GFR could not be an
independent determinant of arterial stiffness in nondiabetic
CKD patients in multivariable regression analysis.
To investigate which factors profoundly influence
increased arterial stiffness in nondiabetic CKD patients, we
performed a subgroup analysis of the PWV according to the GA
levels and eGFR. The subgroup with both an increased GA and
impaired renal function also had the highest PWV compared
with the other subgroups. Interestingly, GA levels showed a
significantly positive correlation only in CKD patients with
impaired renal function compared with those in CKD patients
with eGFRcr-cys 60mL/min/1.73m2. Taken together, these
findings suggested that nondiabetic CKD patients with
increased GA and impaired renal function should be closely
monitored for the development of arterial stiffness.
There are several limitations to this report. Our obser-
vations were cross-sectional in nature with a small sample size.
Medicine  Volume 95, Number 16, April 2016Therefore, a lack of understanding regarding the exact relation-
ship between GA and arterial stiffness still exists. Prospective
studies should be performed to determine whether increased GA
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.can predict the progression of arterial stiffness in CKD. Second,
urinary glycosylated protein levels were not obtained; therefore,
we could not determine whether increased GA levels were
induced by impaired renal clearance or glycemic status. How-
ever, only nondiabetic CKD patients with lower mean GA
levels than those reported for diabetic patients were enrolled
in this study. Therefore, increased GA itself could be mean-
ingful in the progression of vasculopathy as a risk for CVD in
nondiabetic CKD patients, regardless of impaired renal clear-
ance. Finally, baPWV was used as a measurement of arterial
stiffness instead of carotid-femoral PWV (cfPWV).37,38
Recently, baPWV has been shown to represent both central
and peripheral arterial stiffness and is regarded as a useful tool
for evaluating the risk assessment of CVD towing to the ease of
the measurement technique relative to that of cfPWV.38
In conclusion, GA showed a significant correlation with
baPWV andwas the independent risk factor affecting baPWV in
nondiabetic CKD patients. Additionally, patients who have
higher GA levels together with lower eGFRcr-cys should be
monitored for arterial stiffness carefully. The measurement of
serum GA concentrations may be predictive of arterial stiffness
in nondiabetic CKD patients.
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